Antidiabetic effects of pterosin A, a small-molecular-weight natural product, on diabetic mouse models

Diabetes

Volumn 62, Issue 2, 2013, Pages 628-638

  Hsu, Feng Lin ^a   Huang, Chun Fa ^b   Chen, Ya Wen ^b   Yen, Yuan Peng ^c   Wu, Cheng Tien ^c   Uang, Biing Jiun ^d   Yang, Rong Sen ^c   Liu, Shing Hwa ^c,e  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; DEXAMETHASONE; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INSULIN; METFORMIN; NATURAL PRODUCT; PHOSPHOENOLPYRUVATE CARBOXYKINASE (ATP); PROTEIN KINASE; PTEROSIN A; STREPTOZOCIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DIABETES MELLITUS; ENZYME PHOSPHORYLATION; GLUCOGENESIS; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN RESISTANCE; LIPID DIET; LIVER CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TREATMENT DURATION;

ANIMALS; BIOLOGICAL AGENTS; BIOLOGICAL TRANSPORT; CELLS, CULTURED; DEXAMETHASONE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLUCOSE; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORTER TYPE 4; HUMANS; HYPERGLYCEMIA; INDANS; INSULIN; INSULIN RESISTANCE; LIVER; MALE; MICE; MUSCLE, SKELETAL; SESQUITERPENES;

EID: 84873024799     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0585     Document Type: Article

References (50)

1. Unwin N, Whiting D, Guariguata L, Ghyoot G, Gan D, Eds. IDF Diabetes Atlas. 5th Ed. Brussels, Belgium, International Diabetes Federation. 2011. Available from http://www.idf.org/diabetesatlas. Accessed 11 April 2012.
2. Martinez-Hervas S, Romero P, Hevilla EB, et al. Classical cardiovascular risk factors according to fasting plasma glucose levels. Eur J Intern Med 2008;19: 209-213
3. Lasker RD. The diabetes control and complications trial. Implications for policy and practice. N Engl J Med 1993;329:1035-1036
4. Krentz AJ, Bailey CJ. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005;65:385-411
5. Cheng AY, Fantus IG. Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ 2005;172:213-226
6. Mishra R, Shuaib M. Shravan, Mishra PS. A review on herbal antidiabetic drugs. J App Pharm Sci 2011;1:235-237
7. Jarald E, Joshi SB, Jain DC. Diabetes and herbal medicines. Iran J Pharm Ther 2008;7:97-106
8. Wais M, Nazish I, Samad A, et al. Herbal drugs for diabetic treatment: an updated review of patents. Recent Pat Antiinfect Drug Discov 2012;7:53-59
9. Ajikumaran Nair S, Shylesh BS, Gopakumar B, Subramoniam A. Antidiabetes and hypoglycaemic properties of Hemionitis arifolia (Burm.) Moore in rats. J Ethnopharmacol 2006;106:192-197
10. Chen J, Chen X, Lei Y, et al. Vascular protective potential of the total flavanol glycosides from Abacopteris penangiana via modulating nuclear transcription factor-kB signaling pathway and oxidative stress. J Ethno-pharmacol 2011;136:217-223
11. Haider S, Nazreen S, Alam MM, Gupta A, Hamid H, Alam MS. Anti-inflammatory and anti-nociceptive activities of ethanolic extract and its various fractions from Adiantum capillus veneris Linn. J Ethnopharmacol 2011;138:741-747
12. Lei YF, Chen JL, Wei H, Xiong CM, Zhang YH, Ruan JL. Hypolipidemic and anti-inflammatory properties of Abacopterin A from Abacopteris penangiana in high-fat diet-induced hyperlipidemia mice. Food Chem Toxicol 2011;49: 3206-3210
13. Sheridan H, Frankish N, Farrell R. Smooth muscle relaxant activity of pterosin Z and related compounds. Planta Med 1999;65:271-272
14. Takahashi M, Fuchino H, Sekita S, Satake M. In vitro leishmanicidal activity of some scarce natural products. Phytother Res 2004;18:573-578
15. Ouyang DW, Ni X, Xu HY, Chen J, Yang PM, Kong DY. Pterosins from Pteris multifida. Planta Med 2010;76:1896-1900
16. Huang CF, Chen YW, Yang CY, et al. Extract of lotus leaf (Nelumbo nu-cifera) and its active constituent catechin with insulin secretagogue activity. J Agric Food Chem 2011;59:1087-1094
17. Yen YP, Tsai KS, Chen YW, Huang CF, Yang RS, Liu SH. Arsenic inhibits myogenic differentiation and muscle regeneration. Environ Health Per-spect 2010;118:949-956
18. Chen YW, Huang CF, Tsai KS, et al. The role of phosphoinositide 3-kinase/Akt signaling in low-dose mercury-induced mouse pancreatic b-cell dysfunction in vitro and in vivo. Diabetes 2006;55:1614-1624
19. Sasaki K, Cripe TP, Koch SR, et al. Multihormonal regulation of phos-phoenolpyruvate carboxykinase gene transcription. The dominant role of insulin. J Biol Chem 1984;259:15242-15251
20. Lu TH, Hsieh SY, Yen CC, et al. Involvement of oxidative stress-mediated ERK1/2 and p38 activation regulated mitochondria-dependent apoptotic signals in methylmercury-induced neuronal cell injury. Toxicol Lett 2011; 204:71-80
21. Ryu HS, Park SY, Ma D, Zhang J, Lee W. The induction of microRNA targeting IRS-1 is involved in the development of insulin resistance under conditions of mitochondrial dysfunction in hepatocytes. PLoS ONE 2011;6:e17343
22. Swanston-Flatt SK, Day C, Bailey CJ, Flatt PR. Traditional plant treatments for diabetes. Studies in normal and streptozotocin diabetic mice. Dia-betologia 1990;33:462-464
23. Lazar MA. How obesity causes diabetes: not a tall tale. Science 2005;307: 373-375
24. Aronoff SL, Berkowitz K, Shreiner B, Want L. Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr 2004;17:183-190
25. Klip A. The many ways to regulate glucose transporter 4. Appl Physiol Nutr Metab 2009;34:481-487
26. Morgan BJ, Chai SY, Albiston AL. GLUT4 associated proteins as therapeutic targets for diabetes. Recent Pat Endocr Metab Immune Drug Discov 2011;5:25-32
27. Zierath JR, He L, Gumà A, Odegoard Wahlström E, Klip A, Wallberg-Henriksson H. Insulin action on glucose transport and plasma membrane GLUT4 content in skeletal muscle from patients with NIDDM. Diabetologia 1996;39:1180-1189
28. Wallberg-Henriksson H, Zierath Jr. GLUT4: a key player regulating glucose homeostasis? Insights from transgenic and knockout mice (review). Mol Membr Biol 2001;18:205-211
29. Consoli A, Nurjhan N, Capani F, Gerich J. Predominant role of gluconeo-genesis in increased hepatic glucose production in NIDDM. Diabetes 1989; 38:550-557
30. Gastaldelli A, Toschi E, Pettiti M, et al. Effect of physiological hyper-insulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 2001;50:1807-1812
31. Friedman JE, Sun Y, Ishizuka T, et al. Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorti-coids in genetically obese db/db transgenic mice. J Biol Chem 1997;272: 31475-31481
32. Quinn PG, Yeagley D. Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:423-437
33. Gómez-Valadés AG, Vidal-Alabró A, Molas M, et al. Overcoming diabetes-induced hyperglycemia through inhibition of hepatic phosphoenolpyruvate carboxykinase (GTP) with RNAi. Mol Ther 2006;13:401-410
34. Burcelin R, Dolci W, Thorens B. Glucose sensing by the hepatoportal sensor is GLUT2-dependent: in vivo analysis in GLUT2-null mice. Diabetes 2000;49:1643-1648
35. Slieker LJ, Sundell KL, Heath WF, et al. Glucose transporter levels in tissues of spontaneously diabetic Zucker fa/fa rat (ZDF/drt) and viable yellow mouse (Avy/a). Diabetes 1992;41:187-193
36. Hardie DG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology 2003;144:5179-5183
37. Hardie DG. The AMP-activated protein kinase pathway-new players upstream and downstream. J Cell Sci 2004;117:5479-5487
38. Feifel E, Obexer P, Andratsch M, et al. p38 MAPK mediates acid-induced transcription of PEPCK in LLC-PK(1)-FBPase(+) cells. Am J Physiol Renal Physiol 2002;283:F678-F688
39. Cao W, Collins QF, Becker TC, et al. p38 Mitogen-activated protein kinase plays a stimulatory role in hepatic gluconeogenesis. J Biol Chem 2005;280: 42731-42737
40. Berasi SP, Huard C, Li D, et al. Inhibition of gluconeogenesis through transcriptional activation of EGR1 and DUSP4 by AMP-activated kinase. J Biol Chem 2006;281:27167-27177
41. Horike N, Sakoda H, Kushiyama A, et al. AMP-activated protein kinase activation increases phosphorylation of glycogen synthase kinase 3b and thereby reduces cAMP-responsive element transcriptional activity and phosphoenolpyruvate carboxykinase C gene expression in the liver. J Biol Chem 2008;283:33902-33910
42. Cline GW, Johnson K, Regittnig W, et al. Effects of a novel glycogen syn-thase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 2002;51:2903-2910
43. Kaidanovich-Beilin O, Eldar-Finkelman H. Long-term treatment with novel glycogen synthase kinase-3 inhibitor improves glucose homeostasis in ob/ob mice: molecular characterization in liver and muscle. J Pharmacol Exp Ther 2006;316:17-24
44. Huerta MG, Nadler JL. Oxidative stress, inflammation, and diabetic complications. In Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, Lippincott Williams & Wilkins, 2004, p. 1485-1501
45. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-1119
46. Furukawa S, Fujita T, Shimabukuro M, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-1761
47. Prabhakar SS. Role of nitric oxide in diabetic nephropathy. Semin Nephrol 2004;24:333-344
48. Størling J, Binzer J, Andersson AK, et al. Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. Diabetologia 2005;48:2039-2050
49. Liu D, Pavlovic D, Chen MC, Flodström M, Sandler S, Eizirik DL. Cytokines induce apoptosis in beta-cells isolated from mice lacking the inducible isoform of nitric oxide synthase (iNOS-/-). Diabetes 2000;49:1116-1122
50. Maxwell SR. Prospects for the use of antioxidant therapies. Drugs 1995;49: 345-361